Trials / Withdrawn
WithdrawnNCT00349518
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
A Phase II Study of Dasatinib (BMS-354825) in Subjects With Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome positive acute lymphoblastic leukemia. The efficacy of the drug in this kind of patients will also further be documented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2007-01-01
- First posted
- 2006-07-07
- Last updated
- 2016-02-17
Locations
20 sites across 6 countries: Hungary, Italy, Netherlands, Poland, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT00349518. Inclusion in this directory is not an endorsement.